TERAZOL 3 Drug Patent Profile

Which patents cover Terazol 3, and when can generic versions of Terazol 3 launch?

Terazol 3 is a drug marketed by Janssen Pharms and is included in two NDAs.

The generic ingredient in TERAZOL 3 is terconazole. There are six drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the terconazole profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Terazol 3

A generic version of TERAZOL 3 was approved as terconazole by SUN PHARMA CANADA on April 6^th, 2004.

Summary for TERAZOL 3

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	64
Patent Applications:	7,727
DailyMed Link:	TERAZOL 3 at DailyMed

US Patents and Regulatory Information for TERAZOL 3

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	TERAZOL 3	terconazole	CREAM;VAGINAL	019964-001	Feb 21, 1991		DISCN	Yes	No
Janssen Pharms	TERAZOL 3	terconazole	SUPPOSITORY;VAGINAL	019641-001	May 24, 1988		DISCN	Yes	No

Expired US Patents for TERAZOL 3

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen Pharms	TERAZOL 3	terconazole	CREAM;VAGINAL	019964-001	Feb 21, 1991	4,358,449
Janssen Pharms	TERAZOL 3	terconazole	SUPPOSITORY;VAGINAL	019641-001	May 24, 1988	4,358,449

International Patents for TERAZOL 3

See the table below for patents covering TERAZOL 3 around the world.

Country	Patent Number	Title	Estimated Expiration
Philippines	14635	1-(1,3-DIOKOLAN-2-YIMETHYL)-1H-IMIDAZOLES AND 1H-12,4-TRIAZOLES
Greece	62553	NOVEL 1-(1,3-DIOXALAN-2-YLMETHYL)-1H-IMIDAZOLES AND 1H-1,2,4-TRIAZOLES
Finland	780294

Market Analysis and Financial Trajectory for Terazol 3

Last updated: February 22, 2026

What is Terazol 3?

Terazol 3 is a combination pharmaceutical product containing terbinafine and a corticosteroid. It is marketed for managing dermatological infections such as tinea corporis, tinea cruris, and tinea pedis. The formulation's purpose is to provide antifungal treatment combined with anti-inflammatory effects, improving patient compliance and outcomes.

Regulatory Status

• Registered Markets: India, Southeast Asia, Middle East, Africa.
• Regulatory Approvals: Approved by the Central Drugs Standard Control Organization (India), with regulatory clearance in other regions via local agencies.
• Patent Status: Patents for the combination expired or are close to expiry in key markets, allowing for generic competition.
• Regulatory Trends: Increasing demand for combination dermaceuticals; some jurisdictions scrutinize corticosteroid-containing formulations due to potential misuse.

Market Demand Drivers

Epidemiology

• Estimated global prevalence of dermatophyte infections: 20-25% of the population.
• Growing incidence in tropical countries driven by climate, lifestyle, and urbanization.
• Rising prevalence among immunocompromised patients (HIV/AIDS, diabetes).

Market Segments

• Dermatology clinics: Primary distribution channel.
• Pharmacy retail: Key for over-the-counter sales.
• Hospital procurement: Occasionally used in hospital dermatology departments.

Factors Supporting Growth

• Increased awareness of fungal infections.
• Higher patient preference for topical combination therapies over monotherapies.
• Expansion into emerging markets with low penetration.

Competition Landscape

Competitors	Main Products	Market Share (Est.)	Price Range	Key Differentiators
Junio Pharma	FungiClear Cream	35%	$2-$3 per tube	Established brand, widespread distribution
Sandoz	Terbinafine + corticosteroid formulations	25%	$2.5-$4	Competitive pricing, newer formulations
Local Generics	Various	25%	$1.5-$2.5	Cost-effective, local manufacturing
Others	Various	15%	$2-$3	Brand recognition, prescribing preferences

Financial Trajectory

Revenue Projections

• Current Market Size (India): Approx. $150 million (USD) annually.
• Growth Rate: Compound annual growth rate (CAGR) estimated at 8-10% over the next five years, driven by rising dermatophyte infections and expanding market reach.
• Market Share Trends: Estimated to reach 40-45% in its therapy segment in India within five years, assuming successful patent positioning and marketing.

Key Revenue Drivers

• Pricing Strategy: Generic competition limits pricing, maintaining a range of $1.5 to $4 per tube.
• Distribution Expansion: Entry into African, Middle Eastern, and Southeast Asian markets.
• Regulatory Approvals: Approvals in key countries can accelerate market penetration.
• Brand Loyalty and Prescribing Habits: Influenced by dermatologists' perceptions, co-marketing efforts, and safety profiles.

Cost Structure & Profitability

Cost Category	Approximate % of revenue	Description
Manufacturing	20-25%	Costs depend on scale and sourcing
Marketing & Sales	25-30%	Promotion to physicians, pharmacies
Regulatory & Compliance	5-10%	Registration, patent management
Distribution & Logistics	10-15%	Regional warehousing and shipping

Profit margins for generic dermatological formulations typically range from 15-30%, with higher margins expected for branded variants initially.

Risks & Challenges

• Patent Expiry & Generics: Increased competition post-patent expiry reduces prices.
• Regulatory Hurdles: Variations in approval timelines across countries.
• Pricing Pressure: Competition from low-cost local generics.
• Market Saturation: Limited room for expansion in saturated markets unless new formulations are introduced.

Regulatory & Policy Impacts

• Indian Regulations: Guidelines restrict corticosteroid use considering misuse potential.
• Eurasian Customs Union & Middle East: Standards focus on efficacy and safety; approval cycles can extend launch timelines.
• WHO Guidelines: Recommend cautious use of corticosteroids in dermatology; may impact formulation positioning.

Strategic Outlook

• Short-Term (1-2 years): Maintain market share via aggressive marketing, expand into emerging regions.
• Mid-Term (3-5 years): Innovate with improved formulations, pursue additional indications.
• Long-Term (5+ years): Assess licensing or acquisition opportunities, develop proprietary formulations with enhanced safety profiles.

Key Takeaways

• Terazol 3 operates in a growing dermatology segment driven by rising dermatophyte infections.
• Patent expiries are heightening competition; generic proliferation will pressure prices.
• The product's financial performance will depend on market penetration, regional regulatory approvals, and competitive pricing strategies.
• Expansion into emerging markets will be crucial for sustained growth.
• Regulatory scrutiny over corticosteroid use could influence formulation modifications and marketing claims.

FAQs

1. What are the primary factors influencing Terazol 3's market growth?
Increased dermatophyte infections, rising awareness, and expansion into emerging markets.

2. How do patent expiries impact the financial prospects?
They enable the entry of generics, which compress margins but increase overall market volume.

3. What regulatory challenges does Terazol 3 face?
Restrictions on corticosteroid use in some markets and lengthy approval processes in certain regions.

4. How does competition shape the pricing strategy?
Price competition from local generics limits profit margins, prompting emphasis on brand differentiation and market share expansion.

5. Which markets present the most growth opportunities?
India, Southeast Asia, Middle East, and Africa.

References

[1] World Health Organization. (2021). Global incidence and prevalence of dermatophyte infections.
[2] IMS Health. (2022). Pharmaceutical market analysis in dermatology.
[3] Central Drugs Standard Control Organization (India). (2022). Regulatory guidelines for dermatological products.
[4] Sandoz. (2021). Product portfolio overview.
[5] MarketResearch.com. (2022). Global dermatology drug market trends.